Skip to main content

Table 2 The organs parameters of YL529 after oral administration 6000 mg/kg YL529 with a single dose in SD rats

From: A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities

Index

Vehicle

YL529

Vehicle

YL529

Female(♀)

Female (♀)

Male (♂)

Male (♂)

Heart (%)

0.41 ± 0.08

0.42 ± 0.09

0.43 ± 0.05

0.42 ± 0.06

Liver (%)

3.11 ± 0.10

3.13 ± 0.09

3.09 ± 0.10

3.09 ± 0.13

Spleen (%)

0.23 ± 0.03

0.25 ± 0.03

0.23 ± 0.09

0.24 ± 0.04

Lung (%)

0.43 ± 0.05

0.43 ± 0.06

0.44 ± 0.11

0.42 ± 0.09

Kidney (%)

0.37 ± 0.06

0.38 ± 0.09

0.36 ± 0.08

0.38 ± 0.09

  1. Data were expressed as the mean ± SD compared with vehicle. SPSS (SPSS, IL) software was used for statistical analysis (n = 10; *p < 0.05)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us